Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

Share Price Information for Atlantic Lithium (ALL)

Share Price is delayed by 15 minutes
Get Live Data
16.45    0.00 (0.00%)
Bid:
0.00
Ask:
16.90
Spread: 0.45 (2.736%)
Market Cap: £131.85m
ALL Live PriceLast checked at - London Stock Exchange

Intraday Atlantic Lithium Share Chart

Trading Update

24 Jun 2013 07:00

RNS Number : 6463H
Allocate Software PLC
24 June 2013
 



24 June 2013

 

ALLOCATE SOFTWARE PLC

("Allocate" or "the Company")

 

Full Year Trading Update

 

Allocate Software (AIM: ALL), the leading provider of workforce and compliance optimisation solutions, announces an update on trading for its financial year ended 31 May 2013. The Company's audited results will be announced in the week commencing 22 July 2013.

 

Overview

 

Allocate delivered a very strong second half performance with full year results in line with market expectations for both revenue and EBITA. The Company's cash performance has materially exceeded analysts' expectations due to the continuing transition in the Company's business model to one based more on recurring revenues and due to improvements in working capital.

 

Business

 

The Healthcare business achieved another successful year securing a significant number of agreements for both new products and new customers.

 

UK Healthcare bookings are ahead of revenue because the number of recurring orders secured has been higher than anticipated. The financial effect of this is that cash, deferred revenue and contracted, unbilled orders in hand are higher than anticipated. As a result, this will increase the visibility and predictability of future years' revenue streams.

 

The number of new HealthRoster customers secured by the Company was slightly fewer than the previous financial year but met management's expectations for the second half of the current year. Several of the new customers secured were competitor displacements and HealthRoster renewals continued at the previously recorded 100% renewal rate.

 

The Allocate Cloud, launched in July, has exceeded management original plans with new customers entering agreements in addition to existing customers who have already licensed the software, committing to the Cloud service. A further positive impact of this performance is on cash flow, as noted above.

 

Sales of the Medics products enjoyed a good year with a number of new customers signing contracts and a high renewal rate of annual subscriptions. Multiyear renewals have been secured with substantially more customers than anticipated demonstrating high levels of customer satisfaction. A further beneficial impact of the multiyear renewals is on cash flow, as noted above.

 

The migration from HealthRoster V9 to V10 continues in line with management plans. Customers that have migrated are located primarily in the UK, along with customers in the USA and Australia.

 

The Defence business had a productive year securing a major contract with Royal Australian Airforce as well as securing a series of important professional services contract extensions.

 

The Maritime business had a successful year securing a new offshore services customer in addition to closing a number of important follow on licence and services contract extensions.

 

Ian Bowles, Chief Executive Officer of Allocate commented: "2012 was a very important year for Allocate. We launched HealthRoster V10, our most important product for many years and we launched the Allocate Cloud, a completely new HealthRoster service that has been extremely well received by our customers and prospects. Sales of our Medics portfolio of applications exceeded management plans and we continued to secure our 100% renewal rate on HealthRoster. Both the Defence and Maritime businesses again performed solidly.

 

"At the same time as delivering revenue in line with expectations we continued our transition to a business with higher recurring and deferred revenues. Although revenue growth has been masked by both a large order in the prior year and the move to higher recurring and deferred revenues, billings and cash show more significant growth and more fairly reflect the true underlying progress that Allocate has achieved this year.

 

"We remain well placed to support the broader healthcare market in general and specifically the NHS in its goals of improving patient care whilst driving improvements in efficiency."

 

Enquiries:

 

Allocate Software plc

Ian Bowles - Chief Executive Officer

Chris Gale - Chief Financial Officer

Martin Jeffries - Marketing Director

 

Tel: +44 (0) 20 7355 5555

Numis Securities

Nominated adviser - Michael Meade / Simon Willis/ Richard Thomas

Corporate Broking - James Black

 

Tel: +44 (0) 20 7260 1000

Gable Communications

Justine James / John Bick

 

Tel: +44 (0) 20 7193 7463

M: +44 (0) 7525 324431

 

About Allocate Software plc

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include: Healthcare and Defence.

 

At the core of the business is Allocate's workforce optimisation software, which organisations use to deploy the right people with the right skills, to the right place at the right time. Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA, Australia and Malaysia.

 

Allocate is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUAVBRONANUAR
Date   Source Headline
23rd Nov 20239:39 amRNSUpdated Quarterly Activities and Cash Flow Report
22nd Nov 20237:00 amRNSProject Development Update
16th Nov 20237:00 amRNSInvestor Presentation - Noosa Mining Conference
15th Nov 20237:00 amRNSRejection of Non-Binding Indicative Offers
14th Nov 20237:00 amRNSGrant of Highly Prospective Licences for Lithium
10th Nov 20237:00 amRNSConference Attendance
7th Nov 20237:00 amRNSAdditional Resource Extension Drilling Planned
1st Nov 20237:00 amRNSChange of Registered Office
31st Oct 20237:05 amRNSNotice of AGM
31st Oct 20237:00 amRNSQuarterly Activities and Cash Flow Report
20th Oct 20237:00 amRNSMining Lease Granted for Ewoyaa Lithium Project
19th Oct 202311:35 amRNSStatement re Media Speculation
13th Oct 20237:00 amRNSConference Attendance
10th Oct 20237:00 amRNSApproval to Divert Transmission Lines at Ewoyaa
29th Sep 20239:55 amRNSInvestor Presentation
28th Sep 20237:00 amRNS2023 Annual Financial Report
21st Sep 20237:00 amRNSNotice of Results and Investor Presentation
15th Sep 20237:00 amRNSConference Attendance
8th Sep 20237:05 amRNSInvestor Presentation
8th Sep 20237:00 amRNSUS$32.9m Strategic Investment
6th Sep 20237:00 amRNSResource and Exploration Drilling Results
4th Sep 20238:45 amRNSConference Attendance
30th Aug 20237:00 amRNSIssue of Equity - ESOP Options
22nd Aug 20237:00 amRNSIssue of Equity - Exercise of ESOP Options
17th Aug 20237:00 amRNSPartner Commits to Ewoyaa Development Funding
15th Aug 20237:00 amRNSMOU Signed for By-product Feldspar Study
10th Aug 20239:14 amRNSPCA Dealings
9th Aug 20239:30 amRNSDirector/PDMR Dealings
8th Aug 20237:00 amRNSResource and Exploration Drilling Results
7th Aug 20233:13 pmRNSStatement re Media Speculation
31st Jul 20237:00 amRNSQuarterly Activities and Cash Flow Report
19th Jul 20237:00 amRNSConference Attendance
13th Jul 20237:00 amRNSAppointment of Flotation Scoping Study Partner
30th Jun 20237:00 amRNSInvestor Presentation
29th Jun 20238:21 amRNSEwoyaa Definitive Feasibility Study
29th Jun 20237:17 amRNSEwoyaa Definitive Feasibility Study
23rd Jun 202311:00 amRNSBoard Appointments
20th Jun 20237:00 amRNSInitial Infill Drilling Results
16th Jun 20237:00 amRNSConference Attendance
13th Jun 20237:00 amRNSCorporate Update - Resignation of Director
1st Jun 20237:00 amRNSBoard Changes
26th May 20237:00 amRNSDTC Eligibility for OTCQX Electronic Trading
17th May 20237:00 amRNSConference Attendance
16th May 20237:00 amRNSAppointment of Chief Executive Officer
4th May 20237:00 amRNSConference Attendance
28th Apr 20237:00 amRNSQuarterly Activities and Cash Flow Report
26th Apr 20237:00 amRNSInternational Lithium Association Membership
19th Apr 20237:00 amRNSInfill Drilling and Passive Seismic Survey
6th Apr 20237:00 amRNSIssue of Equity – Exercise of ESOP Options
31st Mar 20237:00 amRNSIssue of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.